Live data · NADAC + Part D CY24 · reviewed daily

Morphine (Duramorph)

Opioid Agonist class · 15 generic manufacturers · 62 ANDAs filed at FDA.

First FDA approval1984-09-18
Generic availableYes · 15 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$108.2M in CY2024 Part D spend3.8M claims · 823K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.043/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.187
Across all dosage forms in distribution.
Highest NADAC
$0.310
Wide spread — brand-strength NDCs still in market.
Plans with PA
829 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Morphine used for?

Morphine is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Morphine?

Yes. 62 ANDAs filed at FDA, 15 generic manufacturers currently shipping.

How much does my plan pay for Morphine?

Across 329 Part D plans, Morphine averages $0.187/unit (NADAC). Lowest available: $0.043/unit. Highest in distribution: $0.310/unit.

Is Morphine on the FDA shortage list?

Yes. Morphine is currently listed as an active FDA shortage.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.